Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies.

Allman, M; Tallantyre, E; Robertson, N P

Allman, M; Tallantyre, E; Robertson, N P.

Allman M; Department of Neurology, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN, UK.
Tallantyre E; Department of Neurology, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN, UK.
Robertson NP; Division of Psychological Medicine and Clinical Neuroscience, Department of Neurology, Cardiff University, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN, UK.

J Neurol ; 269(4): 2259-2261, 2022 04.

Article in English | MEDLINE | ID: covidwho-1739323

Subject(s)

COVID-19; Multiple Sclerosis; COVID-19/prevention & control; COVID-19 Vaccines; Humans; Multiple Sclerosis/drug therapy; SARS-CoV-2; Vaccination

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Multiple Sclerosis Topics: Vaccines Limits: Humans Language: English Journal: J Neurol Year: 2022 Document Type: Article Affiliation country: S00415-022-11053-7

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google